Proshares Trust ZBIO
ZBIO
$28.08 -0.10 (-0.35%)
At close: Oct 21, 2026 · 4:00 PM EDT

Zenas BioPharma (ZBIO) EBIT Margin (2023 - 2026)

Updated

Zenas BioPharma's EBIT Margin was -10765.90% in Q2 2026.

Analysis

Zenas BioPharma (ZBIO) EBIT Margin (2023 - 2026) Analysis & Trends

On a trailing twelve-month basis, Zenas BioPharma's EBIT Margin was -47557.30% through Jun 30, 2026, down 46296.63 percentage points year-over-year; for FY2025, it came in at -3830.57%, down 552.81 percentage points from FY2024.

  • In earlier years, EBIT Margin was -3277.76% in FY2024 (-3203.47 pp) and -74.29% in FY2023.
  • The Q2 2026 figure marks the highest quarterly EBIT Margin since Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 28.21%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 37.86%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -3.52%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 32.97%
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 20.57%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 34.95%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -133.21%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 28.37%
10 Zenas BioPharma 1.77 Bn 1.09 Bn - -10,765.90%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -10,765.90%
Mar 31, 2025 -373.30%
Dec 31, 2024 -1,112.46%
Sep 30, 2023 71.25%
API Access

Zenas BioPharma EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=ZBIO&period=max&api_key=YOUR_API_KEY